Related Experiment Video
Updated: Mar 1, 2026

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Published on: May 4, 2018
Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy
Joseph P Lynch1, George G Zhanel2, Nina M Clark3
1Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California.
Abstract:
Pseudomonas aeruginosa (PA), a nonlactose fermenting gram-negative bacillus, is a common cause of nosocomial infections in critically ill or debilitated patients, particularly ventilator-associated pneumonia (VAP), and infections of bloodstream, urinary tract, intra-abdominal, wounds/skin/soft tissue. PA rarely affects healthy individuals, but may cause serious infections in patients with chronic structural lung disease, comorbidities, advanced age, impaired immune defenses, or with medical devices (e.g., urinary or intravascular catheters, foreign bodies). Treatment of pseudomonal infections is difficult, as PA is intrinsically resistant to multiple antimicrobials, and may acquire new resistance determinants even while on antimicrobial therapy. Mortality associated with pseudomonal VAP or bacteremias is high (> 35%) and optimal therapy is controversial. Over the past three decades, antimicrobial resistance among PA has escalated globally, via dissemination of several international multidrug-resistant “epidemic” clones. We review the emergence of antimicrobial resistance to this pathogen, and discuss approaches to therapy (both empirical and definitive).
Insights
Pseudomonas aeruginosa (PA) causes severe hospital infections, especially in vulnerable patients. Rising antimicrobial resistance makes treating PA difficult, increasing mortality risks.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Pseudomonas aeruginosa (PA) is a Gram-negative bacillus frequently causing nosocomial infections in critically ill patients.
- PA infections occur in ventilator-associated pneumonia (VAP), bloodstream, urinary tract, and wound infections, posing significant challenges.
- Intrinsic and acquired antimicrobial resistance complicates treatment, leading to high mortality rates, particularly for VAP and bacteremia.
Purpose of the Study:
- To review the emergence and global escalation of antimicrobial resistance in Pseudomonas aeruginosa.
- To discuss current and future therapeutic strategies for managing PA infections.
Main Methods:
- Literature review focusing on antimicrobial resistance trends in Pseudomonas aeruginosa.
- Analysis of treatment approaches for pseudomonal infections, including empirical and definitive therapies.
Main Results:
- Antimicrobial resistance in PA has significantly increased globally over the past three decades.
- Multidrug-resistant epidemic clones of PA have disseminated internationally.
- High mortality rates (>35%) are associated with pseudomonal VAP and bacteremias, with ongoing therapeutic controversies.
Conclusions:
- The escalating antimicrobial resistance of Pseudomonas aeruginosa necessitates urgent attention and revised therapeutic strategies.
- Effective management of PA infections requires a comprehensive approach addressing both resistance patterns and treatment options.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
06:42Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
Published on: September 27, 2024
Related Concept Videos
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Antibiotic Selection
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Antimicrobial Effectiveness